Halozyme Therapeutics (HALO) PT Raised to $22 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $124.83 --0%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 40
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 40
Join SI Premium – FREE
JPMorgan raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $22.00 (from $19.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CLSA Upgrades Singapore Airlines Ltd. (SIA:SP) (SINGF) to Hold (3)
- Westports Holdings Bhd (WPRTS:MK) PT Raised to MYR8.44 at CLSA
- Aditya Birla Sun Life AMC (ABSLAMC:IN) PT Lowered to INR1,230 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
